205 related articles for article (PubMed ID: 24589156)
1. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R; Thompson A; Gangar P; Duvic M
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
[TBL] [Abstract][Full Text] [Related]
2. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Duvic M; Kim YH; Zinzani PL; Horwitz SM
Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
[No Abstract] [Full Text] [Related]
3. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
6. Multicenter photopheresis intervention trial in early-stage mycosis fungoides.
Talpur R; Demierre MF; Geskin L; Baron E; Pugliese S; Eubank K; Zic JA; Miller DR; Tharp M; Bohjanen K; Duvic M
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):219-27. PubMed ID: 21575927
[TBL] [Abstract][Full Text] [Related]
7. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Rupoli S; Canafoglia L; Goteri G; Leoni P; Brandozzi G; Federici I; Micucci G; Giantomassi F; Mozzicafreddo G; Alterini R; Filosa G; Ricotti G; Simonacci M; Scortechini AR; Zizzi A; Pimpinelli N
Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
[TBL] [Abstract][Full Text] [Related]
9. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
12. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
13. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
14. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
15. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
16. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Horwitz SM; Kim YH; Foss F; Zain JM; Myskowski PL; Lechowicz MJ; Fisher DC; Shustov AR; Bartlett NL; Delioukina ML; Koutsoukos T; Saunders ME; O'Connor OA; Duvic M
Blood; 2012 May; 119(18):4115-22. PubMed ID: 22394596
[TBL] [Abstract][Full Text] [Related]
17. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M
Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320
[TBL] [Abstract][Full Text] [Related]
18. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):T547-T554. PubMed ID: 38653368
[TBL] [Abstract][Full Text] [Related]
19. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
[TBL] [Abstract][Full Text] [Related]
20. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]